GENFIT Reports Strong 2025 Financials, Highlights Pipeline Progress

Biopharmaceutical company sees revenue growth, cash runway through 2028 as key programs advance

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, reported its fourth quarter 2025 financial results and provided a corporate update. The company ended the year with €101.1 million in cash and cash equivalents, driven by strong royalty revenue from Ipsen's sales of the PBC drug Iqirvo® (elafibranor) and milestone payments. GENFIT's pipeline of ACLF and cholangiocarcinoma programs also continued to progress, with positive early data and plans to advance into later-stage trials.

Why it matters

GENFIT's financial performance and pipeline progress demonstrate the company's ability to successfully develop and commercialize therapies for underserved liver disease patients. The strong cash position and anticipated future milestones provide the resources to further advance the company's R&D efforts in areas of high unmet need.

The details

GENFIT reported 2025 revenues of €65.4 million, driven by €21.8 million in royalties from Iqirvo® sales and €43.6 million in milestone payments, including a €17 million ($20 million) milestone triggered by Iqirvo® exceeding $200 million in first-year net sales. The company ended the year with €101.1 million in cash and cash equivalents, which it expects will fund operations beyond the end of 2028. GENFIT's pipeline also advanced, with positive early data from the G1090N program in ACLF and encouraging results from the Phase 1b study of GNS561 in cholangiocarcinoma. Ipsen also initiated a global Phase 3 trial for Iqirvo® in primary sclerosing cholangitis (PSC), representing a significant market opportunity.

  • GENFIT reported its Q4 2025 financial results on February 26, 2026.
  • In January 2026, GENFIT received a €30 million payment from the second installment of its Royalty Financing agreement.
  • The first commercial milestone payment of €17 million ($20 million) from Ipsen's Iqirvo® sales was received one year ahead of schedule.

The players

GENFIT

A biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases.

Ipsen

A global biopharmaceutical company that markets Iqirvo® (elafibranor) for the treatment of primary biliary cholangitis (PBC) under a long-term strategic partnership with GENFIT.

Got photos? Submit your photos here. ›

What they’re saying

“We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline focused on ACLF and support general corporate purposes.”

— GENFIT (biospace.com)

The takeaway

GENFIT's strong financial performance and pipeline progress demonstrate its ability to successfully develop and commercialize therapies for underserved liver disease patients. The company's robust cash position and anticipated future milestones provide the resources to further advance its R&D efforts in areas of high unmet need, such as ACLF and cholangiocarcinoma.